Global Molecular Diagnostics Market (2021 to 2031) - Featuring Abbott, Agilent Technologies and LungLife AI Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, Application, Technology, and End User - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

The global molecular diagnostics market is projected to reach $24,228.0 million by 2031 from $10,914.6 million in 2020, at a CAGR of 7.38% during the forecast period 2021-2031.

Market Report Coverage - Molecular Diagnostics Market Segmentation

• Products (Kits and Consumables, Systems, Software and Other Products)
• Testing Location (Laboratory Testing and Point-of-Care (POC) Testing)
• Application (Core Molecular Diagnostics, Reproductive Genetics, Companion Diagnostics (CDx), Liquid Biopsy, and Others)
• Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing, Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, In-situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies)
• End User (Hospitals, Diagnostics Centers, Out-Patient Clinics/General Practitioners, Research Laboratories, and Other End Users)

Key Questions Answered in this Report:

• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
• What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
• What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
• How is each segment of the global molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key developmental strategies implemented by the major players to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for molecular diagnostics?
• Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which molecular diagnostic product type has the most promising growth?
• What are the key applications in the global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
• What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
• Who are the primary end-users of the global molecular diagnostics market? Which is the fastest-growing end-user segment in the global molecular diagnostics market?
• Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
• What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application and end user dominate these regions?
• What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
• Which technologies are anticipated to break through the current molecular diagnostic regime?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will these enhance the reimbursement scenario?
• What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?

Market Dynamics

Drivers

• A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
• Growth in the Biomarker Identification Market and Advancements in Molecular Techniques
• Increase in Awareness and Acceptance of Personalized Medicines on a Global Level
• Significant External Funding for Executing Research and Development Exercises

Challenges

• Uncertain Reimbursement Scenario
• Lack of High-Complexity Testing Centers
• Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests

Opportunities

• Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations
• Rise of Next-Generation Ultrasensitive Molecular Diagnostics
• Novel Revenue Streams

Companies Mentioned

• Abbott
• Agilent Technologies, Inc.
• Becton, Dickinson and Company (BD)
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Danaher
• F. Hoffmann-La Roche Ltd
• Guardant Health
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Invivoscribe, Inc.
• ICON plc
• LungLife AI, Inc.
• QIAGEN
• QuantuMDx Group Ltd.
• Siemens Healthcare GmbH
• Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/1f3d1j